Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention

• Published in: Current oncology (Toronto) Vol. 31; no. 9; pp. 5709 - 5721
• Main Authors: Perez, Aleymi M, Haberland, Nicole I, Miteva, Mariya, Wikramanayake, Tongyu C
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.09.2024; MDPI
• Subjects: Alopecia; Alopecia - chemically induced; Alopecia - prevention & control; Animals; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - adverse effects; Baldness; Bimatoprost; Cancer; Chemotherapy; docetaxel; Docetaxel - therapeutic use; Humans; minoxidil; Neoplasms - drug therapy; Prevalence; Prevention; Review; scalp cooling; Taxoids - adverse effects; Taxoids - therapeutic use; minoxidil; alopecia; scalp cooling; docetaxel; prevention
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol31090423

Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer. Docetaxel exerts its anti-cancer effects through inhibition of the cell cycle and induction of proapoptotic activity. However, docetaxel also impacts rapidly proliferating normal cells in the scalp hair follicles (HFs), rendering the HFs vulnerable to docetaxel-induced cell death and leading to chemotherapy-induced alopecia (CIA). In severe cases, docetaxel causes persistent or permanent CIA (pCIA) when hair does not grow back completely six months after chemotherapy cessation. Hair loss has severe negative impacts on patients' quality of life and may even compromise their compliance with treatment. This review discusses the notable prevalence of docetaxel-induced CIA and pCIA, as well as their prevention and management. At this moment, scalp cooling is the standard of care to prevent CIA. Treatment options to promote hair regrowth include but are not limited to minoxidil, photobiomodulation (PBMT), and platelet-rich plasma (PRP). In addition, a handful of current clinical trials are exploring additional agents to treat or prevent CIA. Research models of CIA, particularly human scalp HF organ culture and mouse models with human scalp xenografts, will help expedite the translation of bench findings of CIA prevention and/or amelioration to the clinic.